Results 1 to 10 of about 9,966 (258)

Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. [PDF]

PLoS ONE, 2015
This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia.
Thibault B Ali, Thomas R Schleret, Brian M Reilly, Winston Yuchen Chen, Ruben Abagyan   +4 more
doaj   +6 more sources

Mitapivat-Associated Adverse Effects and Potential Mechanistic: Insights From Real-World Data. [PDF]

J Cell Mol Med
Journal of Cellular and Molecular Medicine, Volume 29, Issue 19, October 2025.
Liang G, Liu Q.
europepmc   +2 more sources

Real-world pharmacovigilance study on neonatal congenital anomalies associated with maternal drug exposure using the FDA Adverse Event Reporting System [PDF]

Therapeutic Advances in Drug Safety
Background: Congenital anomalies represent a significant public health concern, with maternal drug exposure during pregnancy being a potential modifiable risk factor.
Jingping Zheng, Zhenpo Zhang, Lin Ma, Ling Su   +3 more
doaj   +2 more sources

Exploring the top 30 drugs associated with drug-induced thrombotic microangiopathy based on the FDA adverse event reporting system [PDF]

Frontiers in Pharmacology
BackgroundDrug-induced thrombotic microangiopathy (TMA) significantly impacts patient health and quality of life. This study aims to conduct an exploratory analysis of TMA reports and the most frequently associated drugs in the FDA Adverse Event ...
Yi Yin, Fanmin Meng, Yanjiao Fan
doaj   +2 more sources

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database

Frontiers in Oncology, 2022
BackgroundImmune checkpoint inhibitors (ICIs), the treatment of multiple cancer types, can be associated with respiratory system adverse events (AEs).
Chanjuan Cui, Lei Deng, Wenqing Wang, Xiayang Ren, Yanfeng Wang, Wei Cui   +5 more
doaj   +1 more source

Mifepristone Adverse Events Identified by Planned Parenthood in 2009 and 2010 Compared to Those in the FDA Adverse Event Reporting System and Those Obtained Through the Freedom of Information Act

Health Services Research & Managerial Epidemiology, 2021
Background As part of the accelerated approval of mifepristone as an abortifacient in 2000, the Food and Drug Administration (FDA) required prescribers to report all serious adverse events (AEs) to the manufacturer who was required to report them to the ...
Christina A. Cirucci, Kathi A. Aultman, Donna J. Harrison   +2 more
doaj   +1 more source

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. [PDF]

, 2017
Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of ...
Abagyan, Ruben, Atayee, Rabia, Cohen, Isaac V, Makunts, Tigran   +3 more
core   +2 more sources

Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.

PLoS ONE, 2021
IntroductionAnticholinergic adverse effects (AEs) are a problem for elderly people. This study aimed to answer the following questions. First, is an analysis of anticholinergic AEs using spontaneous adverse drug event databases possible?
Junko Nagai, Yoichi Ishikawa
doaj   +1 more source

Assessing Cancer Signal during Oral Antiplatelet Therapy in the Food and Drug Administration Adverse Event Reporting System: Mission Impossible

TH Open, 2018
Whether aggressive prolonged dual antiplatelet therapy (DAPT) promotes solid cancer risks remains a critical unsolved issue. Since the evidence from randomized trials, affiliated U.S.
Victor Serebruany, Moo Hyun Kim, Christian Thevathasan, Thomas Marciniak   +3 more
doaj   +1 more source

Assessing the 2004-2018 fentanyl misusing issues reported to an international range of adverse reporting systems [PDF]

, 2019
© 2019 Schifano, Chiappini, Corkery and Guirguis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Chiappini, Stephania, Corkery, John, Guirguis, Amira, Schifano, Fabrizio   +3 more
core   +4 more sources